Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
Next-generation retinal disease treatments: Advancing care in nAMD and DME

Next-generation retinal disease treatments: Advancing care in nAMD and DME

Lynda Charters
June 23rd 2025
Article
Genetic link found between instant coffee consumption and dry AMD

Genetic link found between instant coffee consumption and dry AMD

Lynda Charters
June 20th 2025
Article
Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Sydney M Crago
June 19th 2025
Article
Anonymous $40 million gift received by University of Colorado Anschutz Medical Campus Ophthalmology Department

Anonymous $40 million gift received by University of Colorado Anschutz Medical Campus Ophthalmology Department

Martin David Harp
June 10th 2025
Article
Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 8th 2025
Article
NIH scientists develop new surgical technique for grafting tissue in the retina

NIH scientists develop new surgical technique for grafting tissue in the retina

Kassi Filkins
May 29th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.